Oncolytics Biotech Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ONCY | CRDF | CSBR | OKUR | APLM | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 55.70M | 67.60M | 67.23M | 104.89M | 55.38M | 198.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.1 | -1.6 | 48.3 | -1.7 | -29.2 | -1.5 |
| Price/book | -8.7 | 2.2 | 17.3 | 0.6 | -12.8 | 9.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −58.42% | −61.33% | −29.80% | −18.04% | +42.64% | −58.91% |
| Today | +8.92% | +0.67% | 0.00% | +3.60% | −8.83% | +1.22% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ONCY news ›FDA Roundup: Oncology Approvals, Submissions, and Designations in October 2026
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation. FDA Roundup: Oncology Approvals, Submissions, and Designations in October 2026…
Oncoinvent outlines Phase III of ~500-600 patients while extending runway into 2H 2027
Oncoinvent Q3 2026 earnings call: Phase II recruitment, cash runway to 2027, and key safety and efficacy readouts ahead. Earnings Call Insights: Oncoinvent ASA (BRRGF) Q3 2026 - “By the end of Q3, we have recruited 71 patients” and “we are…
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the…
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in t... Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual…
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunothe... Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing…
Targeted Oncology Is Now Targeted Onc
New Name, Same Connection to Care Targeted Oncology is now Targeted Onc. Beginning today, the franchise that has long served community oncologists and hematologists carries a new name and a new logo, along with a sharper statement of what…
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
100% of responding patients survived for longer than one year FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer SAN DIEGO, Oct.…
How IRA, MFN, and HTA are rewriting oncology launch strategy
In this Q&A, Paolo Correale, SVP of global access and pricing at EVERSANA, and Alan Crowther, general manager, global pricing, access, and digital solutions at EVERSANA, discuss how oncology companies are adapting their launch strategies…
The OncFive: Top Oncology Articles for the Week of 10/18
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Intratumoral Cancer Therapies Market Demonstrates Long-Term Growth Potential At 12% CAGR
The landscape of intratumoral cancer therapies is evolving rapidly driven by significant advances in medical technology and a deeper understanding of targeted cancer treatment As new innovations emerge the market is set to experience…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- kalkinemedia.com2
- stocktitan.net2
- baystreet.ca1
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.